Cipla signs multi-regional licensing deal with Formosa for eye disorder

Cipla Limited has entered into an exclusive licensing agreement with Formosa Pharmaceuticals to commercialize clobetasol propionate ophthalmic suspension, 0.05% (APP13007) for post-operative inflammation and pain following ocular surgery in 11 countries. The USFDA approved product offers a convenient dosing regimen and significant patient benefits.